Esperite N.V.

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, CLARI.PA has a market cap of 1.6B. Regarding current trading prices, ESP.AS is priced at €0.01, while CLARI.PA trades at €4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas CLARI.PA's P/E ratio is -110.65. In terms of profitability, ESP.AS's ROE is +2.64%, compared to CLARI.PA's ROE of -0.00%. Regarding short-term risk, ESP.AS is more volatile compared to CLARI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check CLARI.PA's competition here

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, ORP.PA has a market cap of 1.3B. Regarding current trading prices, ESP.AS is priced at €0.01, while ORP.PA trades at €8.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas ORP.PA's P/E ratio is 0.06. In terms of profitability, ESP.AS's ROE is +2.64%, compared to ORP.PA's ROE of +0.77%. Regarding short-term risk, ESP.AS is more volatile compared to ORP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check ORP.PA's competition here

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, GDS.PA has a market cap of 1.2B. Regarding current trading prices, ESP.AS is priced at €0.01, while GDS.PA trades at €10.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas GDS.PA's P/E ratio is -14.51. In terms of profitability, ESP.AS's ROE is +2.64%, compared to GDS.PA's ROE of -0.07%. Regarding short-term risk, ESP.AS is more volatile compared to GDS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check GDS.PA's competition here

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, KORI.PA has a market cap of 778.6M. Regarding current trading prices, ESP.AS is priced at €0.01, while KORI.PA trades at €7.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas KORI.PA's P/E ratio is 29.44. In terms of profitability, ESP.AS's ROE is +2.64%, compared to KORI.PA's ROE of +0.01%. Regarding short-term risk, ESP.AS is more volatile compared to KORI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check KORI.PA's competition here

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, LNA.PA has a market cap of 289.4M. Regarding current trading prices, ESP.AS is priced at €0.01, while LNA.PA trades at €28.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas LNA.PA's P/E ratio is 13.29. In terms of profitability, ESP.AS's ROE is +2.64%, compared to LNA.PA's ROE of +0.07%. Regarding short-term risk, ESP.AS is more volatile compared to LNA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check LNA.PA's competition here

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, PNSB.BR has a market cap of 245K. Regarding current trading prices, ESP.AS is priced at €0.01, while PNSB.BR trades at €0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas PNSB.BR's P/E ratio is N/A. In terms of profitability, ESP.AS's ROE is +2.64%, compared to PNSB.BR's ROE of N/A. Regarding short-term risk, ESP.AS is more volatile compared to PNSB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check PNSB.BR's competition here

ESP.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESP.AS stands at 0. In comparison, MLSBT.PA has a market cap of 0. Regarding current trading prices, ESP.AS is priced at €0.01, while MLSBT.PA trades at €5.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESP.AS currently has a P/E ratio of -0.01, whereas MLSBT.PA's P/E ratio is -17.10. In terms of profitability, ESP.AS's ROE is +2.64%, compared to MLSBT.PA's ROE of -0.10%. Regarding short-term risk, ESP.AS is more volatile compared to MLSBT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ESP.AS.Check MLSBT.PA's competition here